title: The value of pre-scheduled bone scintigraphies in breast cancer.
abstract: During the first 10 years of Danish Breast Cancer Cooperative Group (DBCG), the subcommittee on bone scintigraphy has focused on the value of bone scintigraphy at the time of operation in all patients and then yearly in those considered to be primarily operable (stage I and II). Out of 1175 patients examined at time of operation, bone metastases could be verified by x-ray or histology in only 16, of whom the majority had bone pain and/or spread to other organs. Similarly, around 2.5% per year for the first 3 postoperative years and about 1% per year during the next 4 postoperative years had bone metastases verified by x-ray or histology within 12 months after the latest scheduled bone scintigraphy. It is concluded that bone scintigraphy is of no value in primarily operable patients with breast cancer, and that the examination should be reserved for patients with symptoms and/or signs of bone metastases and for patients with relapse.
authors.affiliation: Department of Clinical Physiology/Nuclear Medicine, Herlev Hospital, University of Copenhagen, Denmark.
authors.forename: H S
authors.initials: HS
authors.lastname: Thomsen
authors.forename: J O
authors.initials: JO
authors.lastname: Lund
authors.forename: O
authors.initials: O
authors.lastname: Munck
authors.forename: N
authors.initials: N
authors.lastname: Rossing
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000191:economics / Q000556:secondary*; D001943:Breast Neoplasms / Q000601:surgery; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D011877:Radionuclide Imaging